FDA Breaks Its Silence on Hemp CBD in Food: What the Latest Agency Signals Mean for Ingredient Buyers

For years, FDA's position on hemp-derived CBD in food and dietary supplements has been the most significant unresolved regulatory question in the hemp ingredient supply chain. FDA's 2019 guidance document acknowledged that CBD cannot lawfully be added to food under the Food, Drug and Cosmetic Act's drug exclusion rule — given the prior approval of Epidiolex as a CBD drug — while simultaneously declining to enforce that position against the market that had already developed around hemp-derived CBD.

That posture of benign neglect has been shifting. In spring 2026, FDA sent a series of signals suggesting the agency is preparing to move toward a clearer regulatory position on hemp-derived CBD in food and supplements — one that would have significant implications for the B2B ingredient supply chain.

What FDA Has Said and Done Recently

Warning letters with a new tone. FDA's recent warning letters to hemp CBD companies have shifted from the agency's prior focus on disease claims to a broader posture that questions the legal basis for CBD in food products regardless of the claims made. This represents a shift from "you can sell CBD in food if you don't make drug claims" to "the legal status of CBD in food remains unresolved and we are prepared to act on that ambiguity."

GRAS pathway signaling. FDA officials have indicated in public meetings that the agency views a formal Generally Recognized as Safe (GRAS) determination for hemp-derived CBD as the most viable pathway to legal clarity for CBD as a food ingredient. A GRAS determination would remove the drug exclusion barrier by establishing CBD as a food ingredient with a safety record independent of the Epidiolex approval. Several companies have submitted GRAS notifications; FDA has not yet responded to any of them.

Dietary supplement pathway comments. In response to industry petitions, FDA has indicated that the dietary supplement pathway for CBD — which requires a different legal analysis than the food additive pathway — is being actively reviewed. The agency has not committed to a timeline, but the fact that FDA is engaging with the question rather than deferring it entirely represents a change from the prior several years.

Coordination with USDA and DEA. FDA has been coordinating with USDA on the hemp ingredient provisions of the 2024 Farm Bill framework and with DEA on the laboratory registration requirement. This interagency coordination suggests that the broader hemp regulatory ecosystem is moving toward a more defined structure that FDA will need to fit itself into.

Why This Matters for B2B Ingredient Buyers

For B2B hemp ingredient buyers — formulators, brands, and manufacturers incorporating hemp-derived CBD into finished products — FDA's posture matters in two distinct ways.

Market access risk. If FDA moves toward formal enforcement of the drug exclusion rule for CBD in food, finished products containing hemp-derived CBD could face regulatory action regardless of their total THC compliance. A product can be perfectly compliant with the November 12 hemp standard and still be subject to FDA enforcement if FDA determines that the CBD in the product was added unlawfully.

Supply chain documentation risk. FDA's GRAS pathway focus, if it leads to formal regulatory action, would require ingredient buyers to ensure their CBD-containing products are sourced from suppliers with documentation that supports a GRAS determination. Suppliers who have invested in safety data, manufacturing documentation, and chain of custody records are better positioned to meet this documentation standard than those who have not.

The Distinction Between THC Compliance and FDA Status

This is the nuance that many hemp brands miss: being compliant with the November 12 hemp standard does not resolve the FDA food ingredient status question for CBD specifically.

The November 12 standard governs the total THC content of hemp products and the testing methodology used to establish that content. It does not address whether hemp-derived CBD is lawfully added to food under FDA's authority. These are two separate regulatory questions with two separate legal bases.

A hemp beverage that contains 0.3mg total THC per container and is tested by a DEA-registered laboratory is compliant with the USDA hemp framework. Whether that same beverage is lawful under FDA's food additive authorities depends on a separate legal analysis that is not resolved by THC compliance alone.

What B2B Buyers Should Do

• Separate your THC compliance documentation from your CBD food safety documentation. These are different issues requiring different documentation.
• Assess your exposure to the drug exclusion rule. If your products contain CBD as a named or prominently featured ingredient in food or beverages, the FDA question is real and material.
• Track the GRAS notification pipeline. A successful GRAS determination for hemp-derived CBD would resolve the food ingredient status question. If and when FDA responds to any pending GRAS notifications, the industry signal will be significant.
• Consider the dietary supplement pathway for CBD-forward products. Products positioned as dietary supplements rather than conventional food face a different FDA legal analysis that may be more tractable near-term.
• Work with ingredient suppliers who maintain comprehensive safety and manufacturing documentation. If FDA moves toward a GRAS pathway, ingredient-level documentation will matter.

Low Gravity Hemp maintains complete ingredient safety documentation, manufacturing records, and supply chain traceability for all hemp-derived ingredients. Contact our team to discuss the documentation requirements relevant to your specific product formulations.